15 August 2017
Syncona
Limited
Issue of shares
pursuant to the 2017 dividend
The Board of Syncona Limited (the "Company") today announces
that a total of 1,564,683 new ordinary shares will be issued in
satisfaction of the payment of the Company’s 2017 dividend to those
qualifying shareholders who did not elect to receive the dividend
in cash. The new ordinary shares, when issued, will rank pari
passu with the existing issued ordinary shares of the Company.
Application has been made to the Financial Conduct Authority for
the shares to be admitted to the Official List, and to the London
Stock Exchange for the shares to be admitted to trading and it is
expected that dealings will commence in the new ordinary shares on
23 August 2017.
[ENDS]
Enquiries
Northern Trust International Fund Administration Services
(Guernsey) Limited
Company Secretary
Tel: 01481 745001
Copies of this announcement and other corporate information can
be found on the company website at:www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders. Our current investment portfolio consists
of seven high quality companies in life science and a leading range
of fund investments.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We are
established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.
Our market leading funds portfolio seeks to generate superior
returns by investing in long only and alternative investment funds.
This represents a productively deployed evergreen funding base
which enables us to take a long term approach to investing in life
sciences as we target the best new opportunities and support our
existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in
UK science, the Wellcome Trust, original founder of Syncona, and
Cancer Research UK, both of which are significant shareholders in
our business. We make a donation of 0.3% of Net Asset Value
to a range of charities each year.